Targeted Therapy for Early-Stage Lung Cancer?
A trial of the molecularly targeted therapy osimertinib for early-stage lung cancer finds that patients who take it go longer without having a cancer recurrence.
Thanks to Lifesaving Cancer Research18,000,000cancer survivors in the United States are living with, through, and beyond their disease.
Your donation to the American Association for Cancer Research helps our more than 58,000 members worldwide drive progress against cancer.
Donate Now